Oncolytics Biotech Inc. (Nasdaq: ONCY) has reported encouraging immune biomarker findings from its ongoing Phase 1/2 anal cancer study, demonstrating that its investigational immunotherapy pelareorep can expand human papillomavirus (HPV)-16-specific T cells and tumor-associated immune-cell populations when combined with a checkpoint inhibitor. The findings provide new evidence linking treatment-related immune activation with tumor shrinkage in patients with previously treated squamous cell anal cancer.
The translational analysis found that six of 14 evaluable patients experienced expansion of HPV-16-specific T-cell clones, with tumor shrinkage observed in four of those patients. Separately, seven of eight evaluable patients demonstrated more than twofold increases in selected immune-activation biomarkers after one treatment cycle, strengthening the biological rationale for further investigation of pelareorep across HPV-associated malignancies.
The company announced the findings in connection with the Society for Immunotherapy of Cancer Annual Meeting, building on earlier clinical observations suggesting that pelareorep combined with a checkpoint inhibitor may improve treatment responses in advanced anal cancer. However, the small patient numbers and absence of a randomized control group mean the results remain exploratory rather than definitive evidence of clinical benefit.
How Oncolytics Biotech’s pelareorep trial demonstrated HPV-specific T-cell expansion in anal cancer patients
The ongoing Phase 1/2 GOBLET study is evaluating pelareorep in combination with the immune checkpoint inhibitor atezolizumab in patients with unresectable squamous cell anal cancer whose disease has progressed after previous treatment. Investigators are examining whether pelareorep can influence the tumor immune environment and strengthen responses to checkpoint inhibition. The latest translational findings focus on immune-cell expansion, inflammatory biomarkers and the relationship between these changes and tumor responses.
Among 14 patients evaluated for HPV-16-specific immune activity, six demonstrated expansion of T-cell clones recognizing the viral antigen. Four of those six patients also experienced measurable reductions in tumor size, suggesting an association between HPV-directed immune activity and anticancer responses.
Another analysis examined tumor-infiltrating lymphocyte clones detected in peripheral blood after three treatment cycles. All four evaluable patients demonstrated expansion of these immune-cell populations, accompanied by two complete responses and two partial responses.
The four responding patients also showed expansion of at least one HPV-16-specific T-cell clone. These findings suggest that the combination may stimulate immune populations capable of recognizing virus-associated tumor characteristics.
However, the observations do not establish that T-cell expansion directly caused tumor regression. The limited sample size, exploratory nature of the biomarker analyses and potential contribution of atezolizumab must be considered when interpreting the results.
The relationship between immune activity and tumor response remains an important research question. Larger studies will be necessary to determine whether these biological changes consistently predict treatment effectiveness or longer survival.
Why pelareorep’s immune biomarker findings could strengthen checkpoint inhibitor treatment for HPV-driven cancers
Pelareorep is an investigational intravenously administered immunotherapy based on a proprietary formulation of reovirus. The treatment is designed to replicate preferentially in cancer cells while stimulating innate and adaptive immune responses associated with tumor recognition.
Its proposed mechanism involves changes within the tumor microenvironment that may help immune cells identify malignant tissue. These effects include inflammatory signaling and the recruitment or expansion of tumor-infiltrating lymphocytes.
The latest analysis examined three immune-activation biomarkers: CXCL10, interferon-gamma and soluble programmed death-ligand 1. Researchers observed increases exceeding twofold in seven of eight evaluable patients after one cycle of treatment.
CXCL10 participates in immune-cell recruitment, while interferon-gamma contributes to immune activation and cellular responses against infection and cancer. Soluble PD-L1 provides additional information about immune regulatory processes, although its biological interpretation depends on clinical context.
Together, these measurements suggest that treatment was associated with substantial immune-system activity in most patients included in this analysis. However, elevated inflammatory biomarkers are not automatically evidence of effective or durable cancer control.
Checkpoint inhibitors work by reducing inhibitory signals that can limit the immune system’s ability to attack malignant cells. Atezolizumab targets PD-L1, helping restore aspects of antitumor immune activity in appropriately selected treatment settings.
Pelareorep is being investigated as a complementary therapy that could help generate or amplify immune responses before checkpoint inhibition exerts its effects. This strategy is particularly relevant in tumors that demonstrate limited responses to checkpoint inhibitor monotherapy.
HPV-associated cancers represent a potential opportunity because viral proteins can provide recognizable targets for immune cells. However, tumor-associated immune suppression may prevent an adequate response even when relevant antigens are present.
Oncolytics Biotech Chief Medical Officer Thomas Heineman indicated that the observed expansion of HPV-specific T cells and tumor-infiltrating lymphocytes supports further investigation of pelareorep alongside checkpoint inhibitors. He also emphasized the potential relevance of the mechanism across multiple HPV-associated cancers.
The findings suggest that pelareorep may influence biological processes beyond direct viral replication in tumor cells. Its capacity to alter immune signaling could become important if subsequent studies demonstrate that these effects translate into reproducible clinical benefits.
What earlier GOBLET trial results reveal about pelareorep response durability and advanced anal cancer treatment
The newly reported immune biomarker findings build on earlier clinical results from Cohort 4 of the GOBLET study, which evaluated pelareorep combined with atezolizumab in patients with second-line or later squamous cell anal cancer.
Oncolytics previously reported a median duration of response of approximately 15 months in the evaluated cohort. The company described this outcome as favorable compared with historical results for approved checkpoint inhibitor therapy in a similar treatment setting.
It also reported that all responding patients in the relevant analysis survived for more than one year. Median overall survival had not yet been reached at the reported data cutoff, limiting conclusions about longer-term survival outcomes.
The company has stated that its combination regimen generated an objective response rate more than twice that associated with a historical benchmark and increased median response duration by approximately 50%. These comparisons are encouraging but were not derived from a randomized head-to-head trial.
Historical comparisons can be affected by differences in patient characteristics, prior treatments, disease severity and assessment methods. Consequently, they cannot establish that pelareorep provides superior efficacy to an approved treatment.
Squamous cell anal cancer is frequently associated with persistent infection by high-risk HPV types, particularly HPV-16. Although many patients benefit from established treatment approaches, recurrent or metastatic disease can become difficult to manage after standard therapies fail.
The limited availability of effective options in later treatment lines creates an important need for additional therapeutic strategies. Treatments capable of improving response durability without unacceptable toxicity could become valuable additions to the clinical landscape.
Pelareorep has received Fast Track designation from the U.S. Food and Drug Administration for certain previously treated anal cancer patients when combined with a checkpoint inhibitor. The designation may facilitate regulatory interactions but does not establish efficacy or guarantee approval.
Oncolytics has also reported alignment with the FDA regarding the design of a planned pivotal anal cancer study. Future comparative clinical evidence will be essential for determining whether the promising early observations support a potential registration pathway.
How HPV-specific immune responses could expand pelareorep research into cervical and head and neck cancers
The latest findings could have implications beyond anal cancer because several malignancies share HPV-associated biological characteristics. These include cervical cancer and certain oropharyngeal cancers, where viral antigens may provide targets for immune-directed treatment.
Oncolytics is investigating whether pelareorep’s capacity to stimulate HPV-specific T-cell populations could support development across these indications. The company’s broader strategy emphasizes combining its immunotherapy with treatments intended to strengthen antitumor responses.
The potential relevance of HPV-16-specific T-cell expansion provides a scientific rationale for additional research. However, evidence from anal cancer cannot automatically be generalized to cervical, head and neck or other HPV-associated malignancies.
Different tumors possess distinct immune environments, treatment histories and mechanisms of resistance. Dedicated clinical studies will therefore be required to determine whether comparable biological activity produces meaningful outcomes across indications.
Pelareorep has already been administered to more than 1,200 patients across multiple solid tumor programs, providing a substantial body of clinical development experience. Nevertheless, its safety and efficacy must be evaluated within each proposed treatment combination and patient population.
Oncolytics Chief Executive Officer Jared Kelly indicated that the HPV-associated cancer opportunity could support strategic collaborations with larger pharmaceutical companies. Management estimates a potential market opportunity of $3 billion to $5 billion across relevant malignancies, although these figures represent internal commercial projections rather than established future revenue.
The company is also investigating pelareorep in colorectal and pancreatic cancers, reflecting its broader ambition to develop a treatment capable of complementing several oncology therapies.
For the anal cancer program, the immediate scientific priority is establishing whether HPV-specific immune activation provides a consistent marker of clinical response. Researchers must also determine how these responses evolve with repeated treatment and whether they correlate with meaningful improvements in survival or quality of life.
The combination of immune biomarker findings and previously reported response durability provides a rationale for continued investigation. However, additional controlled studies are necessary to confirm treatment effectiveness, characterize safety and identify patients most likely to benefit.
Oncolytics Biotech’s latest findings represent progress in understanding how pelareorep interacts with the immune system in HPV-associated tumors. The next development stage will determine whether the observed immune activity can translate into reproducible clinical benefits and support a broader role for the investigational immunotherapy in cancer treatment.
